Medtronic delivered its strongest annual revenue growth in a decade in fiscal 2026, reporting $36.4 billion in revenue, up 8.4% year over year, while fourth-quarter revenue climbed 9.9% to $9.8 billion. The performance was driven by broad-based growth across the company’s cardiovascular, medical surgical, neuroscience, and diabetes businesses.

The cardiovascular segment was a standout performer, growing 10.1% organically in the fourth quarter. Growth was fueled by strong demand for cardiac rhythm management products and exceptional momentum in cardiac ablation solutions, where revenue surged 78% globally and 124% in the U.S. as Medtronic continued to gain market share.

Medical Surgical also delivered solid results, with organic growth of 5.1%, led by double-digit gains in acute care and monitoring and continued strength in endoscopy. The diabetes business grew 8.1% organically, reflecting sustained adoption of the company’s diabetes management technologies.

Beyond its core businesses, Medtronic advanced several key growth initiatives, including regulatory submissions for its Hugo robotic-assisted surgery platform and new approvals for the Stealth AXiS surgical system. The company also expanded its portfolio through targeted acquisitions and investments in high-growth areas such as cardiovascular care, neurovascular therapies, and neuromodulation.

With strong cash generation, a growing pipeline, and continued investment in innovation, Medtronic enters fiscal 2027 positioned to build on its momentum across some of the fastest-growing segments of the medical technology market, according to the company report.